Celebrity Inventors
Glam girl Heddy Lamar may have used her good looks to good effect on the silver screen, but she put her smarts to better use as an inventor. During World War II, she co-patented a frequency-switching system for torpedo guidance that was considered years ahead of its time.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120107355 | METHOD OF RAPIDLY PRODUCING IMPROVED VACCINES FOR ANIMALS A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on... | 05/03/2012 |
| 20120107354 | VIRAL VACCINE AND PROCESS FOR PREPARING THE SAME The present invention provides a vaccine against a viral infection. The exemplary vaccine comprises a viral antigen of a vaccine strain of a virus; wherein the viral antigen is derived from a virus preparation of the vaccine strain of the virus; wherein the virus prepar... | 05/03/2012 |
| 20120107358 | SUBGENOMIC REPLICONS OF THE FLAVIVIRUS DENGUE The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.... | 05/03/2012 |
| 20120039937 | INDUCTION OF AN IMMUNE RESPONSE AGAINST DENGUE VIRUS USING THE PRIME-BOOST APPROACH The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral ... | 02/16/2012 |
| 20120039936 | INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA) The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furtherm... | 02/16/2012 |
| 20120020957 | DENGUE VIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF The invention relates to antibodies and antigen binding fragments thereof and to cocktails of antibodies and antigen binding fragments that neutralize dengue virus infection without contributing to antibody-dependent enhancement of dengue virus infection. The invention ... | 01/26/2012 |
| 20120021001 | MARKED BOVINE VIRAL DIARRHEA VIRUS VACCINES The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the NS3 domain results in a loss of recognition by a monoclonal antibody raised against wild-type NS3 but wherein viral... | 01/26/2012 |
| 20120014981 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of th... | 01/19/2012 |
| 20120014992 | N-Linked Glycosylation Alteration in E1 Glycoprotein of Classical Swine Fever Virus And Novel Classical Swine Fever Virus Vaccine E1, along with Erns and E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). Our previous studies indicated that glycosylation status of either E2 or Erns strongly influence viral virulence in swine. Here, we have investigated the role of... | 01/19/2012 |
| 20120009216 | EARLY DETECTION OF FLAVIVIRUSES USING THE NS1 GLYCOPROTEIN The invention concerns a method for early detection of a flavivirus-induced infection, comprising the detection of the flavivirus non-structural glycoprotein NS1 in a biological sample during the clinical phase of the infection, by an immunological method using at least... | 01/12/2012 |
| 20120003266 | VIRUS LIKE PARTICLE COMPOSITIONS AND METHODS OF USE The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.... | 01/05/2012 |
| 20120003277 | NANOEMULSION VACCINES The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the sam... | 01/05/2012 |
| 20110318407 | INACTIVATED DENGUE VIRUS VACCINE WITH ALUMINIUM-FREE ADJUVANT The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus.... | 12/29/2011 |
| 20110293659 | METHOD FOR THE ORAL/MUCOSAL VACCINATION BY MEANS OF RECOMBINANT YEASTS Recombinant yeast cells are produced which are used for vaccination, among other uses for the oral vaccination by feeding.... | 12/01/2011 |
| 20110293723 | SYNTHETIC NANOCARRIER COMBINATION VACCINES Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically accepta... | 12/01/2011 |
| 20110287044 | RECOMBINANT CLASSICAL SWINE FEVER VIRUS (CSFV) COMPRISING A MODIFIED E2 PROTEIN AND METHODS FOR GENERATING SAID RECOMBINANT CSFV The invention relates to a recombinant classical swine fever virus (CSFV). A preferred recombinant CSFV comprises a deletion of at least one amino acid in a “TAVSPTTLR” domain of the E2 protein. The invention further relates to a vaccine comprising the recombinant C... | 11/24/2011 |
| 20110287089 | USE OF A SACCHAROMYCES CEREVISIAE MITOCHONDRIAL NUCLEIC ACIDS FRACTION FOR IMMUNE STIMULATION The present invention relates to the use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction and an antigen for the preparation of a pharmaceutical composition intended to orient the immune response toward a Th1 type response directed against said ... | 11/24/2011 |
| 20110268763 | POLYNUCLEOTIDES THAT STIMULATE NEUTROPHILS The polynucleotides of the present invention are complementary to the Initiation Sites of microbes. Invading organisms, sensing the pH and nutrient deprivation of a physiologic environment quickly release these nucleotides triggering rapid growth and mutation—attribut... | 11/03/2011 |
| 20110262394 | DNA CONSTRUCTS ELICITING IMMUNE RESPONSE AGAINST FLAVIVIRUS AND EFFECTIVE ADJUVANTS Aspects of the present invention relate to isolated nucleic acids that encode a consensus DIII domain of protein E and vaccines made using same, and also methods for using the aforementioned to generate in a host an immune response against multiple serotypes of flavivir... | 10/27/2011 |
| 20110262472 | VACCINE COMPOSITIONS FOR THE TREATMENT OF DENGUE FEVER AND USES THEREOF The invention provides compositions, vaccine compositions and pharmaceutical compositions for the treatment, amelioration and/or prevention of dengue fever. The compositions, vaccine compositions and pharmaceutical compositions of the invention comprise a virus-like par... | 10/27/2011 |
| 20110262482 | ANTI-VIRAL COMPOUNDS Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.... | 10/27/2011 |
| 20110243989 | IDNA VACCINES AND METHODS FOR USING THE SAME Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When ... | 10/06/2011 |
| 20110236421 | FLAVIVIRUS HOST RANGE MUTATIONS AND USES THEREOF Methods and compositions concerning mutant flaviviruses with host range mutations. In some embodiments the invention concerns nucleotide sequences that encode mutant flavivirus proteins. Viruses comprising these sequences that display reduced replication in mammalian ce... | 09/29/2011 |
| 20110229520 | MUTANT PESTIVIRUS WITH MUTATIONS IN CORE GENE AND NS3 REGION The present invention relates to mutant Pestiviruses, and vaccines containing said viruses.... | 09/22/2011 |
| 20110223197 | Mucosal and Systemic Immunization with Alphavirus Replicon Particles Mucosal and systemic administration of compositions comprising alphavirus replicon particles to induce immune responses in a subject is described.... | 09/15/2011 |
| 20110212123 | Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based Adjuvant The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least ... | 09/01/2011 |
| 20110206730 | Dengue Chimeric Viruses The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever vi... | 08/25/2011 |
| 20110182941 | Alphavirus and Alphavirus Replicon Particle Formulations and Methods Disclosed are methods for preparing dried (preferably lyophilized) preparations comprising a population of alphaviruses or alphavirus replicon particles, a sugar or polyol, a surfactant and a salt and preparations made by these methods, both in the dried form but also a... | 07/28/2011 |
| 20110182847 | USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxi... | 07/28/2011 |
| 20110182976 | LIPOPLEX-PATCH BASED DNA VACCINE This invention relates to a DNA vaccine preparation in a patch against virus infection comprising a DNA construct incorporated in a liposome, wherein the ratio of DNA to liposome is from 1:1 to 1:10; wherein the DNA vaccine preparation is preferably administrated after ... | 07/28/2011 |
| 20110159033 | WEST NILE VIRUS VACCINE The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection agai... | 06/30/2011 |
| 20110135685 | Edible Vaccines Expressed in Soybeans The present invention relates to vaccines that are made in transgenic soybeans for use in humans, animals of agricultural importance, pets, and wildlife. These vaccines are used as vaccines against viral, bacterial, fungal, parasitic or prion related diseases, cancer an... | 06/09/2011 |
| 20110135686 | Replication-Defective Flavivirus Vaccines and Vaccine Vectors This invention provides replication-defective flavivirus vaccines and vaccine vectors, and corresponding compositions and methods.... | 06/09/2011 |
| 20110110979 | METHOD AND VACCINE FOR OPTIMIZING THE SPECIFIC IMMUNE RESPONSES The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus (HPV) infection or an associated disease or lesion in a subject.... | 05/12/2011 |
| 20110104198 | CONSENSUS SEQUENCES OF CHIKUNGUNYA VIRAL PROTEINS, NUCLEIC ACID MOLECULES ENCODING THE SAME, AND COMPOSITIONS AND METHODS FOR USING THE SAME Consensus CHIKV E1 protein, consensus CHIKV E2 protein, consensus CHIKV capsid protein, or fragments and homologues thereof, and nucleic acid molecules that encode the same are disclosed. A consensus CHIKV Env protein which includes CHIKV E1 consensus protein, CHIKV E2 ... | 05/05/2011 |
| 20110086065 | Lentival Vector-Based Vaccine Methods of eliciting humoral responses, methods of immunization, and methods of vaccination using lentiviral vector are disclosed. Additionally, immunogenic compositions and vaccines for West Nile Virus are disclosed.... | 04/14/2011 |
| 20110081376 | METHOD FOR USING INACTIVATED JAPANESE ENCEPHALITIS VIRUS PARTICLES AS ADJUVANT A method for using inactivated Japanese encephalitis virus particles as an adjuvant of a vaccine is provided. A method for using inactivated Japanese encephalitis virus (JEV) particles as an adjuvant of various vaccines or a mixed vaccine, said JEV particles being obtai... | 04/07/2011 |
| 20110081379 | PURIFICATION METHOD AND METHOD OF PRODUCING VACCINE A method of purifying a virus or viral antigen from a sample solution containing the virus or viral antigen is provided. The method comprises: preparing sintered powder of hydroxyapatite, wherein a specific surface area of particles of the sintered powder is in the rang... | 04/07/2011 |
| 20110064768 | Immunogenic Compositions An immunogenic composition comprising a viral vector, said vector comprising a nucleic acid sequence encoding a C4bp domain or variant or fragment thereof and a nucleic acid sequence encoding an antigen of interest.... | 03/17/2011 |
| 20110059131 | LOCALIZATION AND CHARACTERIZATION OF FLAVIVIRUS ENVELOPE GLYCOPROTEIN CROSS-REACTIVE EPITOPES AND METHODS FOR THEIR USE Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides compri... | 03/10/2011 |
